donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
09969 INNOCARE-B
11.600
+0.120+1.05%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Turnover
76368.7% 1.04B 13490.51% 101.66M 9.38% 1.36M 26.14% 748K
Operating income
76368.7% 1.04B 13490.51% 101.66M 9.38% 1.36M 26.14% 748K
Cost of sales
-- -65.67M -- -9.82M -- -- -- --
Operating expenses
-65.67M -9.82M
Gross profit
71554.4% 977.37M 12177.14% 91.83M 9.38% 1.36M 26.14% 748K
Selling expenses
-337.58% -298.46M -1538.92% -125.03M -1872.47% -68.21M -1040.36% -7.63M
Administrative expenses
-56.44% -139.82M -23.42% -58.6M -40.47% -89.37M -195.22% -47.48M
Research and development expenses
-79.15% -721.58M 20.03% -184.87M -88.99% -402.77M -143.76% -231.16M
Revaluation surplus
49.77% -51.01M -- -- -- -101.56M 70.81% -69.18M
-Changes in the fair value of financial assets
-57.58% -51.01M -- -- -- -32.37M -- --
-Changes in the fair value of other assets
-- -- -- -- -- -69.18M 70.81% -69.18M
Impairment and provision
-- -32K -- -125K -- -- -- --
-Other impairment is provision
-- -32K -- -125K -- -- -- --
Special items of operating profit
-19.7% 216.67M 263.3% 64.46M 586.5% 269.82M -35.46% 17.74M
Operating profit
95.68% -16.88M 36.99% -212.33M -16.84% -390.73M -5.15% -336.96M
Financing cost
-131.96% -2.64M -113.4% -1.04M 40.55% -1.14M 65.36% -485K
Share of profit from joint venture company
-- -604K -- -14K -- -- -- --
Earning before tax
94.87% -20.12M 36.77% -213.38M 81.78% -391.87M -4.84% -337.44M
Tax
-- -46.56M -- 302K -- -- -- --
After-tax profit from continuing operations
82.98% -66.68M 36.85% -213.08M 81.78% -391.87M -4.84% -337.44M
Earning after tax
82.98% -66.68M 36.85% -213.08M 81.78% -391.87M -4.84% -337.44M
Minority profit
-354.04% -2.13M -37.76% -3.66M 94.76% -470K -379.96% -2.66M
Profit attributable to shareholders
83.51% -64.55M 37.45% -209.42M 81.72% -391.4M -4.2% -334.79M
Basic earnings per share
87.5% -0.05 62.79% -0.16 95.71% -0.4 73.94% -0.43
Diluted earnings per share
87.5% -0.05 62.79% -0.16 95.71% -0.4 73.94% -0.43
Currency Unit
CNYCNYCNYCNY
Accounting Standards
HKASHKASHKASHKAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Ernst & Young accounting firm--Ernst & Young accounting firm--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Nuocheng Jianhua Pharmaceutical Co., Ltd. is an investment holding company mainly engaged in biomedical business. The company discovers, develops and commercializes potentially best-in-class and pioneered drugs for the treatment of cancer and autoimmune diseases. The company has established an integrated biomedical platform with internal research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, as well as commercial production and sales.
CEO: Jisong Cui
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...